Researchers from the Francis Crick Institute in the UK revealed the role of a key gene in human embryos in the first few days of development.
They used genome editing technique called CRISPR/Cas9 to stop a key gene from producing a protein called OCT4, which normally becomes active in the first few days of human embryo development.
After the egg is fertilised, it divides until at about seven days it forms a ball of around 200 cells called the 'blastocyst'.
"We were surprised to see just how crucial this gene is for human embryo development, but we need to continue our work to confirm its role," said Norah Fogarty from the Francis Crick Institute.
"Other research methods, including studies in mice, suggested a later and more focused role for OCT4, so our results highlight the need for human embryo research," said Fogarty, first author of the study published in the journal Nature.
"One way to find out what a gene does in the developing embryo is to see what happens when it is not working," said Kathy Niakan from the Francis Crick Institute, who led the research.
The team spent over a year optimising their techniques using mouse embryos and human embryonic stem cells before starting work on human embryos.
To inactivate OCT4, they used CRISPR/Cas9 to change the DNA of 41 human embryos. After seven days, embryo development was stopped and the embryos were analysed.
The embryos used in the study were donated by couples who had undergone in vitro fertilisation (IVF) treatment, with frozen embryos remaining in storage.
The study was done under a research licence and strict regulatory oversight from the Human Fertilisation and Embryology Authority (HFEA), the UK government's independent regulator overseeing infertility treatment and research.
As well as human embryo development, OCT4 is thought to be important in stem cell biology.
'Pluripotent' stem cells can become any other type of cell, and they can be derived from embryos or created from adult cells such as skin cells.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
